Janssen Biotech Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for JANSSEN BIOTECH, and when can generic versions of JANSSEN BIOTECH drugs launch?
JANSSEN BIOTECH has three approved drugs.
There are fourteen US patents protecting JANSSEN BIOTECH drugs.
There are three hundred and fifty-eight patent family members on JANSSEN BIOTECH drugs in forty-seven countries and twenty-eight supplementary protection certificates in fifteen countries.
Summary for Janssen Biotech
| International Patents: | 358 |
| US Patents: | 14 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Janssen Biotech: | See patent lawsuits for Janssen Biotech |
Drugs and US Patents for Janssen Biotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 11,077,106 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | 10,702,508 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | 8,802,689 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | Yes | 9,987,261 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Janssen Biotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Biotech | ZYTIGA | abiraterone acetate | TABLET;ORAL | 202379-001 | Apr 28, 2011 | 5,604,213 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN BIOTECH drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 500 mg | ➤ Subscribe | 2017-08-23 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2015-04-28 |
International Patents for Janssen Biotech Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2018141009 | ⤷ Try a Trial |
| Denmark | 2656841 | ⤷ Try a Trial |
| Portugal | 3590934 | ⤷ Try a Trial |
| Japan | 6027662 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Janssen Biotech Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2368550 | CA 2019 00029 | Denmark | ⤷ Try a Trial | PRODUCT NAME: APALUTAMID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/18/1342 20190116 |
| 3533792 | LUC00236 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: APALUTAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/18/1342 20190116 |
| 2368550 | 300993 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: APALUTAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1342 20190116 |
| 2368550 | C02368550/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: APALUTAMID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67072 19.09.2019 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
